India, April 29 -- A micro-pharma stock trading at Rs. 13.80 has come into focus after the company outlined an aggressive growth plan involving around 30 percent revenue CAGR over the next three years, a major capacity scale-up and expansion across the pharma value chain. The stock currently has a market capitalisation of around Rs. 736.15 crore. Promoter holding stood at 52.68 percent as of March 2026, while FIIs increased their stake from 0.23 percent to 0.32 percent between December and March. DIIs also raised their holding from 2.83 percent in September 2025 to 4.60 percent in March 2026.

Anlon Healthcare Ltd is a Rajkot-based research-driven chemical manufacturer engaged in high-purity pharmaceutical intermediates and active pharmac...